TITLE

Application of adenosine 5'-triphosphate (ATP) infusions in palliative home care: design of a randomized clinical trial

AUTHOR(S)
Beijer, Sandra; van Rossum, Erik; Hupperets, Pierre S.; Spreeuwenberg, Cor; van den Beuken, Marieke; Winkens, Ron A.; Ars, Lisette; van den Borne, Ben E.; de Graeff, Alexander; Dagnelie, Pieter C.
PUB. DATE
January 2007
SOURCE
BMC Public Health;2007, Vol. 7, p4
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Palliative care in cancer aims at alleviating the suffering of patients. A previous study in patients with advanced non-small-cell lung cancer showed that adenosine 5′-triphosphate (ATP) infusions had a favourable effect on fatigue, appetite, body weight, muscle strength, functional status and quality of life. The present study was designed 1. To evaluate whether ATP has favourable effects in terminally ill cancer patients, 2. To evaluate whether ATP infusions may reduce family caregiver burden and reduce the use of professional health care services, and 3. To test the feasibility of application of ATP infusions in a home care setting. Methods/Design: The study can be characterized as an open-labelled randomized controlled trial with two parallel groups. The intervention group received usual palliative care, two visits by an experienced dietician for advice, and regular ATP infusions over a period of 8 weeks. The control group received palliative care as usual and dietetic advice, but no ATP. This paper gives a description of the study design, selection of patients, interventions and outcome measures. Discussion: From April 2002 through October 2006, a total of 100 patients have been randomized. Follow-up of patients will be completed in December 2006. At the time of writing, five patients are still in follow up. Of the 95 patients who have completed the study, 69 (73%) have completed four weeks of follow-up, and 53 (56%) have completed the full eight-week study period. The first results are expected in 2007.
ACCESSION #
29361906

 

Related Articles

  • Palliative higher-dose radiation improved overall survival in NSCLC.  // Hem/Onc Today;10/25/2008, Vol. 9 Issue 19, p29 

    The article discusses a study which showed improvement in the overall survival rate of patients with non-small cell lung cancer who were treated with higher-dose palliative thoracic radiation. Results for symptom palliation, overall survival, toxicity and re-irradiation rate were evaluated in...

  • Non-small cell lung cancer therapy: safety and efficacy in the elderly. Glotzer, Owen S.; Fabian, Thomas; Chandra, Anurag; Bakhos, Charles T. // Drug, Healthcare & Patient Safety;Apr2013, Vol. 5, p113 

    Background: Our objective was to evaluate and review the current literature on the treatment of non-small cell lung cancer (NSCLC) in the elderly. Methods: We selected recent peer-reviewed articles addressing ageing, cancer treatment in the elderly, and lung cancer treatment in the elderly. We...

  • Treatment of advanced non small cell lung cancer. Bareschino, Maria Anna; Schettino, Clorinda; Rossi, Antonio; Maione, Paolo; Sacco, Paola Claudia; Zeppa, Rosario; Gridelli, Cesare // Journal of Thoracic Disease;Jun2011, Vol. 3 Issue 2, p122 

    Lung cancer is the major cause of cancer death in the world. Non Small Cell Lung Cancer (NSCLC) accounts approximately 80-85% of all lung cancer diagnosis; the majority of patients will be diagnosed with non operable, advanced-stage disease. Palliative chemotherapy and/or radiotherapy represent...

  • Factors Driving the Choice of the Best Second-Line Treatment of Advanced NSCLC. Maione, Paolo; Rossi, Antonio; Bareschino, Maria Anna; Sacco, Paola Claudia; Schettino, Clorinda; Falanga, Marzia; Barbato, Valentina; Ambrosio, Rita; Gridelli, Cesare // Reviews on Recent Clinical Trials;Jan2011, Vol. 6 Issue 1, p44 

    Platinum-based chemotherapy, with or without the antiangiogenetic drug bevacizumab, is the standard first-line therapy for patients with advanced non-small-cell lung cancer (NSCLC). The epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) gefitinib has been recently approved as...

  • Brèves de l'AERIO. Michels, J.; Besse, B.; Thibault, C. // Oncologie;Feb2013, Vol. 15 Issue 2, p125 

    No abstract available.

  • Opinion: ImClone/BMS/Merck KGaA: Erbitux approval in lung cancer now likely.  // PharmaWatch: Monthly Review;Jun2008, Vol. 7 Issue 7, p7 

    The author reflects on the effectiveness of Erbitux to increase survival in advanced non-small cell lung cancer. The author relates that compared with 10.1 months for patients treated chemotherapy, the overall survival of patients treated wit Erbitux was 11.3 months. The author added that the...

  • Lung Cancer: RESULTS FROM THE PHASE III PARAMOUNT TRIAL. Melosky, Barbara // Oncology Exchange;Aug2012, Vol. 11 Issue 3, p22 

    The article discusses the results of the phase III Paramount trial on maintenance pemetrexed (pem) with best supportive care (BSC) against placebo with BSC in the patients with advanced nonsquamous non-small cell lung cancer (NSCLC). It says that pem continuation maintenance therapy reduces the...

  • Phase II study of everolimus—erlotinib in previously treated patients with advanced non-small-cell lung cancer. Besse, B.; Leighl, N.; Bennouna, J.; Papadimitrakopoulou, V. A.; Blais, N.; Traynor, A. M.; Soria, J.-C.; Gogov, S.; Miller, N.; Jehl, V.; Johnson, B. E. // Annals of Oncology;Feb2014, Vol. 25 Issue 2, p409 

    Based on the results of a multicenter, open-label, phase II study conducted among patients with previously treated, advanced NSCLC, the combination of everolimus 5 mg/day plus erlotinib 150 mg/day does not warrant further investigation in light of increased toxicity and lack of substantial...

  • A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. Besse, B.; Heist, R. S.; Papadmitrakopoulou, V. A.; Camidge, D. R.; Beck, J. T.; Schmid, P.; Mulatero, C.; Miller, N.; Dimitrijevic, S.; Urva, S.; Pylvaenaeinen, I.; Petrovic, K.; Johnson, B. E. // Annals of Oncology;Feb2014, Vol. 25 Issue 2, p505 

    Everolimus 2.5 mg/day plus granulocyte colony-stimulating factor was identified as the feasible dose given with standard-dose cisplatin–etoposide for treatment-naive extensive-stage small-cell lung cancer (SCLC). Based on the results of this study and a study of everolimus monotherapy for...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics